But for an insurance company, the ROI on curing someone’s hemophilia may be very very large.
On the more consumer side of things, being able to fix some sort of obnoxious but perfectly survivable condition that genetic engineering may be able to solve (say lactose intolerant) may be something that you could sell to a lot of people.
Surely an insurance company would prefer that the patient go elsewhere rather than have to pay $100,000+ every year on treatment. Even if they lose a customer, at least they don’t have that enormous expense.
On the more consumer side of things, being able to fix some sort of obnoxious but perfectly survivable condition that genetic engineering may be able to solve (say lactose intolerant) may be something that you could sell to a lot of people.